A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)

Trial Profile

A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs BGB 324 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 14 Nov 2017 According to a BerGenBio media release, this trial will be presented at at the 2017 San Antonio Breast Cancer Symposium.
    • 19 Oct 2017 According to a BerGenBio ASA media release, first patient has been dosed, and preliminary results are expected at the end of 2018.
    • 18 Aug 2017 According to a BerGenBio ASA media release, the company has completed IPO and the funds from the recent IPO will enable the company to complete the four ongoing phase II trials (NCT02488408, NCT02424617, NCT03184558, NCT03184571) including this trial with read-outs expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top